IFNα induces CCR5 in CD4
Journal
Communications medicine
ISSN: 2730-664X
Titre abrégé: Commun Med (Lond)
Pays: England
ID NLM: 9918250414506676
Informations de publication
Date de publication:
19 Mar 2024
19 Mar 2024
Historique:
received:
03
05
2023
accepted:
07
02
2024
medline:
20
3
2024
pubmed:
20
3
2024
entrez:
20
3
2024
Statut:
epublish
Résumé
Among people living with HIV, elite controllers (ECs) maintain an undetectable viral load, even without receiving anti-HIV therapy. In non-EC patients, this therapy leads to marked improvement, including in immune parameters, but unlike ECs, non-EC patients still require ongoing treatment and experience co-morbidities. In-depth, comprehensive immune analyses comparing EC and treated non-EC patients may reveal subtle, consistent differences. This comparison could clarify whether elevated circulating interferon-alpha (IFNα) promotes widespread immune cell alterations and persists post-therapy, furthering understanding of why non-EC patients continue to need treatment. Levels of IFNα in HIV-infected EC and treated non-EC patients were compared, along with blood immune cell subset distribution and phenotype, and functional capacities in some cases. In addition, we assessed mechanisms potentially associated with IFNα overload. Treatment of non-EC patients results in restoration of IFNα control, followed by marked improvement in distribution numbers, phenotypic profiles of blood immune cells, and functional capacity. These changes still do not lead to EC status, however, and IFNα can induce these changes in normal immune cell counterparts in vitro. Hypothesizing that persistent alterations could arise from inalterable effects of IFNα at infection onset, we verified an IFNα-related mechanism. The protein induces the HIV coreceptor CCR5, boosting HIV infection and reducing the effects of anti-HIV therapies. EC patients may avoid elevated IFNα following on infection with a lower inoculum of HIV or because of some unidentified genetic factor. Early control of IFNα is essential for better prognosis of HIV-infected patients. The treatment for HIV, known as antiretroviral therapy (ART), does not cure HIV but enables individuals to live longer, healthier lives. In this study, we compared immune responses between elite controllers (ECs), who control their HIV infection without any treatment, and ART-treated and untreated patients. We demonstrate that IFNα, a small protein crucial in controlling immune system, is excessively produced at the onset of HIV infection and at levels that persist, resulting in poor HIV control without therapy. We show a mechanism for lack of control of HIV by IFNα. While inhibiting HIV, IFNα also simultaneously increases the HIV co-receptor, CCR5, thereby facilitating virus entry into the target cell. This is avoided by ECs which we hypothesize is associated with a lower infectious inoculum of HIV.
Sections du résumé
BACKGROUND
BACKGROUND
Among people living with HIV, elite controllers (ECs) maintain an undetectable viral load, even without receiving anti-HIV therapy. In non-EC patients, this therapy leads to marked improvement, including in immune parameters, but unlike ECs, non-EC patients still require ongoing treatment and experience co-morbidities. In-depth, comprehensive immune analyses comparing EC and treated non-EC patients may reveal subtle, consistent differences. This comparison could clarify whether elevated circulating interferon-alpha (IFNα) promotes widespread immune cell alterations and persists post-therapy, furthering understanding of why non-EC patients continue to need treatment.
METHODS
METHODS
Levels of IFNα in HIV-infected EC and treated non-EC patients were compared, along with blood immune cell subset distribution and phenotype, and functional capacities in some cases. In addition, we assessed mechanisms potentially associated with IFNα overload.
RESULTS
RESULTS
Treatment of non-EC patients results in restoration of IFNα control, followed by marked improvement in distribution numbers, phenotypic profiles of blood immune cells, and functional capacity. These changes still do not lead to EC status, however, and IFNα can induce these changes in normal immune cell counterparts in vitro. Hypothesizing that persistent alterations could arise from inalterable effects of IFNα at infection onset, we verified an IFNα-related mechanism. The protein induces the HIV coreceptor CCR5, boosting HIV infection and reducing the effects of anti-HIV therapies. EC patients may avoid elevated IFNα following on infection with a lower inoculum of HIV or because of some unidentified genetic factor.
CONCLUSIONS
CONCLUSIONS
Early control of IFNα is essential for better prognosis of HIV-infected patients.
The treatment for HIV, known as antiretroviral therapy (ART), does not cure HIV but enables individuals to live longer, healthier lives. In this study, we compared immune responses between elite controllers (ECs), who control their HIV infection without any treatment, and ART-treated and untreated patients. We demonstrate that IFNα, a small protein crucial in controlling immune system, is excessively produced at the onset of HIV infection and at levels that persist, resulting in poor HIV control without therapy. We show a mechanism for lack of control of HIV by IFNα. While inhibiting HIV, IFNα also simultaneously increases the HIV co-receptor, CCR5, thereby facilitating virus entry into the target cell. This is avoided by ECs which we hypothesize is associated with a lower infectious inoculum of HIV.
Autres résumés
Type: plain-language-summary
(eng)
The treatment for HIV, known as antiretroviral therapy (ART), does not cure HIV but enables individuals to live longer, healthier lives. In this study, we compared immune responses between elite controllers (ECs), who control their HIV infection without any treatment, and ART-treated and untreated patients. We demonstrate that IFNα, a small protein crucial in controlling immune system, is excessively produced at the onset of HIV infection and at levels that persist, resulting in poor HIV control without therapy. We show a mechanism for lack of control of HIV by IFNα. While inhibiting HIV, IFNα also simultaneously increases the HIV co-receptor, CCR5, thereby facilitating virus entry into the target cell. This is avoided by ECs which we hypothesize is associated with a lower infectious inoculum of HIV.
Identifiants
pubmed: 38504093
doi: 10.1038/s43856-024-00453-7
pii: 10.1038/s43856-024-00453-7
doi:
Types de publication
Journal Article
Langues
eng
Pagination
52Informations de copyright
© 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Références
Leon, A. et al. Rate and predictors of progression in elite and viremic HIV-1 controllers. AIDS 30, 1209–1220 (2016).
doi: 10.1097/QAD.0000000000001050
pubmed: 26854807
Maggi, P. et al. Cardiovascular risk and dyslipidemia among persons living with HIV: a review. BMC Infect. Dis. 17, 551 (2017).
doi: 10.1186/s12879-017-2626-z
pubmed: 28793863
pmcid: 5550957
Zhou, Q. et al. Malignancies in people living with HIV. AIDS Rev. https://doi.org/10.24875/AIDSRev.21000057 (2022).
Rasch, M. G. et al. Renal function and incidence of chronic kidney disease in HIV patients: a Danish cohort study. Scand. J. Infect. Dis. 44, 689–696 (2012).
doi: 10.3109/00365548.2012.673730
pubmed: 22680981
Kruger, M. J. & Nell, T. A. Bone mineral density in people living with HIV: a narrative review of the literature. AIDS Res. Ther. 14, 35 (2017).
doi: 10.1186/s12981-017-0162-y
pubmed: 28747190
pmcid: 5530558
Yuan, N. Y. & Kaul, M. Beneficial and adverse effects of cART affect neurocognitive function in HIV-1 infection: Balancing viral suppression against neuronal stress and injury. J. Neuroimmune Pharmacol. 16, 90–112 (2021).
doi: 10.1007/s11481-019-09868-9
pubmed: 31385157
Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295–1300 (1997).
doi: 10.1126/science.278.5341.1295
pubmed: 9360927
Wong, J. K. et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278, 1291–1295 (1997).
doi: 10.1126/science.278.5341.1291
pubmed: 9360926
Neumann, A. U. et al. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. AIDS 13, 677–683 (1999).
doi: 10.1097/00002030-199904160-00008
pubmed: 10397562
Davey, R. T. et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc. Natl. Acad. Sci. USA 96, 15109–15114 (1999).
doi: 10.1073/pnas.96.26.15109
pubmed: 10611346
pmcid: 24781
Deeks, S. G. & Walker, B. D. Human immunodeficiency virus controllers: Mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 27, 406–416 (2007).
doi: 10.1016/j.immuni.2007.08.010
pubmed: 17892849
Lambotte, O. et al. HIV controllers: A homogeneous group of HIV-1–infected patients with spontaneous control of viral replication. Clin. Infect. Dis. 41, 1053–1056 (2005).
doi: 10.1086/433188
pubmed: 16142675
Jiang, C. et al. Distinct viral reservoirs in individuals with spontaneous control of HIV-1. Nature 585, 261–267 (2020).
doi: 10.1038/s41586-020-2651-8
pubmed: 32848246
pmcid: 7837306
Le Buanec, H. et al. Early elevated IFNα is a key mediator of HIV pathogenesis. Comms Med. https://doi.org/10.1038/s43856-024-00454-6 (2024).
Schiavon, V. et al. Microenvironment tailors nTreg structure and function. Proc. Natl. Acad. Sci. USA 116, 6298–6307 (2019).
doi: 10.1073/pnas.1812471116
pubmed: 30846549
pmcid: 6442590
Salazar-Gonzalez, J. F. et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J. Exp. Med. 206, 1273–1289 (2009).
doi: 10.1084/jem.20090378
pubmed: 19487424
pmcid: 2715054
Van der Sluis, R. M. et al. Diverse effects of interferon alpha on the establishment and reversal of HIV latency. PLoS Pathog 16, e1008151 (2020).
doi: 10.1371/journal.ppat.1008151
pubmed: 32109259
pmcid: 7065813
Cocchi, F. et al. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 270, 1811–1815 (1995).
doi: 10.1126/science.270.5243.1811
pubmed: 8525373
Zagury, D. et al. C-C chemokines, pivotal in protection against HIV type 1 infection. Proc. Natl. Acad. Sci. USA 95, 3857–3861 (1998).
doi: 10.1073/pnas.95.7.3857
pubmed: 9520457
pmcid: 19927
Zagury, D. et al. Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS. Proc. Natl. Acad. Sci. USA 95, 3851–3856 (1998).
doi: 10.1073/pnas.95.7.3851
pubmed: 9520456
pmcid: 19926
Poli, A. et al. CD56
doi: 10.1111/j.1365-2567.2008.03027.x
pubmed: 19278419
pmcid: 2673358
Forconi, C. S. et al. A New Hope for CD56negCD16pos NK cells as unconventional cytotoxic mediators: An adaptation to chronic diseases. Front Cell Infect Microbiol 10, 162 (2020).
doi: 10.3389/fcimb.2020.00162
pubmed: 32373555
pmcid: 7186373
Cha, L., de Jong, E., French, M. A. & Fernandez, S. IFN-α exerts opposing effects on activation-induced and IL-7–induced proliferation of T cells that may impair homeostatic maintenance of CD4
Deeks, S. G. et al. Immune activation set point during early HIV infection predicts subsequent CD4+ T cell changes independent of viral load. Blood 104, 942–947 (2004).
doi: 10.1182/blood-2003-09-3333
pubmed: 15117761
Mellors, J. W. et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272, 1167–1170 (1996).
doi: 10.1126/science.272.5265.1167
pubmed: 8638160
Zagury, D. et al. Long-term cultures of HTLV-III–infected T cells: A model of cytopathology of T cell depletion in AIDS. Science 231, 850–853 (1986).
doi: 10.1126/science.2418502
pubmed: 2418502
Orenstein, J. M., Fox, C. & Wahl, S. M. Macrophages as a source of HIV during opportunistic infections. Science 276, 1857–1861 (1997).
doi: 10.1126/science.276.5320.1857
pubmed: 9188531
Stacey, A. R. et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute Hepatitis B and C virus infections. J. Virol 83, 3719–3733 (2009).
doi: 10.1128/JVI.01844-08
pubmed: 19176632
pmcid: 2663284
Hardy, G. A. D. et al. Interferon-α is the primary plasma type-I IFN in HIV-1 infection and correlates with immune activation and disease markers. PLoS One 8, e56527 (2013).
doi: 10.1371/journal.pone.0056527
pubmed: 23437155
pmcid: 3577907
Cha, L. et al. Interferon-alpha, immune activation and immune dysfunction in treated HIV infection. Clin. Transl. Immunol. 3, e10 (2014).
doi: 10.1038/cti.2014.1
Dondi, E., Rogge, L., Lutfalla, G., Uzé, G. & Pellegrini, S. Down-modulation of responses to type I IFN upon T cell activation. J. Immunol 170, 749–756 (2003).
doi: 10.4049/jimmunol.170.2.749
pubmed: 12517937
Le Buanec, H. et al. IFN- and CD46 stimulation are associated with active lupus and skew natural T regulatory cell differentiation to type 1 regulatory T (Tr1) cells. Proc. Natl. Acad. Sci. 108, 18995–19000 (2011).
doi: 10.1073/pnas.1113301108
pubmed: 22065791
pmcid: 3223453
Dutrieux, J. et al. Modified interferon-α subtypes production and chemokine networks in the thymus during acute simian immunodeficiency virus infection, impact on thymopoiesis. AIDS 28, 1101–1113 (2014).
doi: 10.1097/QAD.0000000000000249
pubmed: 24614087
Stoddart, C. A., Keir, M. E. & McCune, J. M. IFN-alpha-induced upregulation of CCR5 leads to expanded HIV tropism in vivo. PLoS Pathog 6, e1000766 (2010).
doi: 10.1371/journal.ppat.1000766
pubmed: 20174557
pmcid: 2824759
Lazear, H. M., Schoggins, J. W. & Diamond, M. S. Shared and distinct functions of type I and type III interferons. Immunity 50, 907–923 (2019).
doi: 10.1016/j.immuni.2019.03.025
pubmed: 30995506
pmcid: 6839410
Migueles, S. A. et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc. Natl. Acad. Sci. USA 97, 2709–2714 (2000).
doi: 10.1073/pnas.050567397
pubmed: 10694578
pmcid: 15994
Claireaux, M. et al. Low CCR5 expression protects HIV-specific CD4+ T cells of elite controllers from viral entry. Nat. Commun. 13, 521 (2022).
doi: 10.1038/s41467-022-28130-0
pubmed: 35082297
pmcid: 8792008
Rolland, M. et al. Molecular dating and viral load growth rates suggested that the eclipse phase lasted about a week in HIV-1 infected adults in East Africa and Thailand. PLoS Pathog 16, e1008179 (2020).
doi: 10.1371/journal.ppat.1008179
pubmed: 32027734
pmcid: 7004303
Lian, X. et al. Signatures of immune selection in intact and defective proviruses distinguish HIV-1 elite controllers. Sci. Transl. Med. 13, eabl4097 (2021).
doi: 10.1126/scitranslmed.abl4097
pubmed: 34910552
pmcid: 9202005
Le Buanec, H. et al. IFNα induces CCR5 in CD4